<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02971345</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-IR-2016</org_study_id>
    <nct_id>NCT02971345</nct_id>
  </id_info>
  <brief_title>Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus</brief_title>
  <official_title>Endovascular Brachytherapy Combined With Stent Placement and Transcatheter Arterial Chemoembolization (TACE) for Treatment of HCC With Main Portal Vein Tumor Thrombus Versus TACE Alone: a Prospective Randomized Controlled Multicentre Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lishui Country People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second People's Hospital of Yibin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZhuHai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan Hospital Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yancheng Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changzhou Wujin People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tengzhou Central People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a prospective and multi-center clinical research in China to compare the efficacy,
      safety and related impact factors between TACE alone and endovascular brachytherapy combined
      with stent placement and TACE for HCC with main portal vein tumor thrombus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is an open random prospective phase III clinical trial conducted by Principal Investigator
      Professor Zhi-ping Yan.Investigators in twenty-seven hospitals in China participate
      in.Patients with unresectable HCC with main portal vein tumor thrombus are enrolled. The
      investigators propose to recruitment 253 patients who are randomly assigned into the combined
      group (treated with endovascular brachytherapy combined with stent placement and TACE) and
      the control group (treated with TACE alone).There are 127 patients in combined group and 126
      patients in control group. The criteria of inclusion and exclusion, and the methods of lab
      tests, imaging modality and treatment procedures are the same.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the date of randomization until the date of death from any cause, assessed up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time To Progression</measure>
    <time_frame>From the date of first procedure of TACE or combined therapy until the time when the disease progresses from an intermediate to an advanced stage as defined by specific events, assessed up to 24 months</time_frame>
    <description>Time to progression follow-up is done at three months interval after lesions defined as stable with treatment of TACE or combined therapy six months after enrollment until lesions are defined as disease progression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">253</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Portal Vein Tumor Thrombus</condition>
  <arm_group>
    <arm_group_label>Endovascular Brachytherapy&amp;Stent&amp;TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transarterial chemoembolization (TACE) is performed immediately following Iodine-125 seed strand and stent implantation.
Epirubicin,ultra-fluid lipiodol and gelatin sponge articles are used in TACE.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Only TACE is performed. Epirubicin, ultra-fluid lipiodol and gelatin sponge articles are used in TACE.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stent and Iodine-125 seed strand implantation</intervention_name>
    <description>The patent second-order branch of the intrahepatic portal vein was punctured with a 22-gauge Chiba needle under ultrasound guidance.Stent and Iodine-125 seed strand are implanted by two 0.035-inch,150-cm-long wire.</description>
    <arm_group_label>Endovascular Brachytherapy&amp;Stent&amp;TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stent</intervention_name>
    <description>Bare stent should be placed through a 7-F, 23-cm-long sheath over the wire.</description>
    <arm_group_label>Endovascular Brachytherapy&amp;Stent&amp;TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Iodine-125 seed</intervention_name>
    <description>The number of Iodine-125 seeds planned to be implanted was calculated by the following formula: N = length of obstructed main portal vein (mm)/4.5 + 4. These seeds were arranged linearly and sealed into a 4-F catheter continuously to construct a Iodine-125 seed strand.</description>
    <arm_group_label>Endovascular Brachytherapy&amp;Stent&amp;TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Epirubicin is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: Epirubicin 30-60 mg per patient,depending on the situation of the patient.</description>
    <arm_group_label>Endovascular Brachytherapy&amp;Stent&amp;TACE</arm_group_label>
    <arm_group_label>TACE alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ultra-fluid lipiodol</intervention_name>
    <description>Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .</description>
    <arm_group_label>Endovascular Brachytherapy&amp;Stent&amp;TACE</arm_group_label>
    <arm_group_label>TACE alone</arm_group_label>
    <other_name>lipiodol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Gelatin sponge articles</intervention_name>
    <description>Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.</description>
    <arm_group_label>Endovascular Brachytherapy&amp;Stent&amp;TACE</arm_group_label>
    <arm_group_label>TACE alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) Hepatocellular carcinoma(HCC) diagnosis confirmed by needle biopsy or by two
             coincidental imaging techniques associated with increased α-fetoprotein according to
             the American Association for the Study of Liver Diseases (AASLD) guidelines;

          -  (2) According to the Barcelona Clinic Liver Cancer staging classification, HCC was
             unsuitable for resection, liver transplantation or percutaneous radiofrequency
             ablation;

          -  (3) Tumor thrombus, a low-attenuation intraluminal filling defect extending from
             intrahepatic portal vein branches adjacent to primary tumor into main portal vein, was
             confirmed by contrast-enhanced abdominal computer tomography (CT) or magnetic
             resonance imaging (MRI)

          -  (4) At least the first-order branch of the intrahepatic portal vein was patent in one
             lobe;

          -  (5) Child-Pugh classification grade A or B;

          -  (6) Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less;

        Exclusion Criteria:

          -  (1) Patients had a history of any therapy for HCC or portal vein tumor thrombus;

          -  (2) Advanced liver disease (bilirubin levels &gt;3 mg/dL, Aspartate transaminase or
             Alanine aminotransferase &gt;5 × upper limit of normal)；

          -  (3) Tumor invade the Inferior Vena Cava, extrahepatic spread;

          -  (4) Any contraindication to an arterial procedure such as impaired clotting tests
             (platelet count below 50 × 109/L or prothrombin activity below 50 %);

          -  (5) Renal failure,cardiac ejection fraction (&lt;50 %) or end-stage disease;

          -  (6) Patients who were not capable of cooperation during the procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhiping Yan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Interventional Radiology, Zhongshan Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianjun Luo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Interventional Radiology, Zhongshan Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zihan Zhang, MD</last_name>
    <phone>+8615901785843</phone>
    <email>zhangzihan0217@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wen Zhang, MD</last_name>
    <phone>+8613774267409</phone>
    <email>wenzhangxiao@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Interventional Radiology, Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianjun Luo, MD</last_name>
      <email>zhangzihan0217@126.com</email>
    </contact>
    <investigator>
      <last_name>Zhinping Yan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianjun Luo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Luo J, Yan Z, Liu Q, Qu X, Wang J. Endovascular placement of iodine-125 seed strand and stent combined with chemoembolization for treatment of hepatocellular carcinoma with tumor thrombus in main portal vein. J Vasc Interv Radiol. 2011 Apr;22(4):479-89. doi: 10.1016/j.jvir.2010.11.029.</citation>
    <PMID>21463757</PMID>
  </results_reference>
  <results_reference>
    <citation>Luo JJ, Zhang ZH, Liu QX, Zhang W, Wang JH, Yan ZP. Endovascular brachytherapy combined with stent placement and TACE for treatment of HCC with main portal vein tumor thrombus. Hepatol Int. 2016 Jan;10(1):185-95. doi: 10.1007/s12072-015-9663-8. Epub 2015 Sep 4.</citation>
    <PMID>26341514</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang M, Fang Z, Yan Z, Luo J, Liu L, Zhang W, Wu L, Ma J, Yang Q, Liu Q. Transarterial chemoembolisation (TACE) combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone: a two-arm, randomised clinical trial. J Cancer Res Clin Oncol. 2014 Feb;140(2):211-9. doi: 10.1007/s00432-013-1568-0. Epub 2013 Dec 28. Erratum in: J Cancer Res Clin Oncol. 2014 Apr;140(4):687-8.</citation>
    <PMID>24374800</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2016</study_first_submitted>
  <study_first_submitted_qc>November 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2016</study_first_posted>
  <last_update_submitted>January 8, 2017</last_update_submitted>
  <last_update_submitted_qc>January 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular carcinoma</keyword>
  <keyword>main portal vein tumor thrombus</keyword>
  <keyword>endovascular brachytherapy</keyword>
  <keyword>stent</keyword>
  <keyword>chemoembolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Ethiodized Oil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

